CAR-T cell combination therapy: the next revolution in cancer treatment

• Published in: Cancer cell international 2022-11, Vol.22 (1), p.1-365, Article 365
• Main Authors: Al-Haideri, Maysoon, Tondok, Santalia Banne, Safa, Salar Hozhabri, maleki, Ali Heidarnejad, Rostami, Samaneh, Jalil, Abduladheem Turki, Al-Gazally, Moaed E., Alsaikhan, Fahad, Rizaev, Jasur Alimdjanovich, Mohammad, Talar Ahmad Merza, Tahmasebi, Safa
• Format: Article
• Language: English
• Subjects: Antigens; Cancer; Cancer therapies; CAR-T cell therapy; Cell therapy; Chemokines; Chemotherapy; Chimeric antigen receptor; Chimeric antigen receptors; Combination therapy; Cytokines; Cytotoxicity; Fibroblasts; Hematological malignancies; Hematology; Kinases; Lymphocytes; Lymphocytes T; Monoclonal antibodies; Review; Solid tumors; Tumor microenvironment; Tumors
• ISSN: 1475-2867; 1475-2867
• DOI: 10.1186/s12935-022-02778-6

In recent decades, the advent of immune-based therapies, most notably Chimeric antigen receptor (CAR)-T cell therapy has revolutionized cancer treatment. The promising results of numerous studies indicate that CAR-T cell therapy has had a remarkable ability and successful performance in treating blood cancers. However, the heterogeneity and immunosuppressive tumor microenvironment (TME) of solid tumors have challenged the effectiveness of these anti-tumor fighters by creating various barriers. Despite the promising results of this therapeutic approach, including tumor degradation and patient improvement, there are some concerns about the efficacy and safety of the widespread use of this treatment in the clinic. Complex and suppressing tumor microenvironment, tumor antigen heterogeneity, the difficulty of cell trafficking, CAR-T cell exhaustion, and reduced cytotoxicity in the tumor site limit the applicability of CAR-T cell therapy and highlights the requiring to improve the performance of this treatment. With this in mind, in the last decade, many efforts have been made to use other treatments for cancer in combination with tuberculosis to increase the effectiveness of CAR-T cell therapy, especially in solid tumors. The combination therapy results have promising consequences for tumor regression and better cancer control compared to single therapies. Therefore, this study aimed to comprehensively discuss different cancer treatment methods in combination with CAR-T cell therapy and their therapeutic outcomes, which can be a helpful perspective for improving cancer treatment in the near future.